Core Viewpoint - In the past year, Innovent Biologics has achieved breakthroughs in multiple disease areas, marking significant advancements in the biopharmaceutical industry in China [1] Group 1: Product Developments - The launch of Tislelizumab (替妥尤单抗 N01) fills a 70-year gap in the treatment of thyroid eye disease in China [1] - Ma Shidu Peptide (玛仕度肽) is recognized as the world's first approved GCG/GLP-1 dual-target weight loss and blood sugar-lowering drug, showcasing the impact of domestic innovative drugs in global academic circles [1] Group 2: Market and Regulatory Environment - Continuous reforms in drug regulation, medical insurance, and capital markets have facilitated the rapid translation of research outcomes into patient benefits [1] Group 3: Strategic Direction - Positioned at the new starting point of the 14th Five-Year Plan, Innovent Biologics aims to enhance its independent R&D capabilities and adhere to a strategy of "innovation as the cornerstone and globalization" [1] - The company plans to deepen domestic and international collaborations to steadily advance towards becoming a world-class biopharmaceutical company [1]
信达生物副总裁李延寿：以原研创新助力健康中国建设